Bombesin-Related Peptides and Neurotensin: Effects on Cancer Growth/Proliferation and cellular signaling in cancer

Handbook of Biologically Active Peptides

Volumn , Issue , 2006, Pages 429-434

  Jensen, Robert T ^a   Moody, Terry W ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b CCR   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33751189441     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369442-3/50064-7     Document Type: Chapter

References (81)

1. Bartholdi MF, Wu JM, Pu H, Troncoso P, Eden PA, Feldman RI In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma. Int J Cancer 1998, 79:82-90.
2. Benya RV, Wada E, Battey JF, Fathi Z, Wang LH, Mantey SA, Coy DH, Jensen RT Neuromedin B receptors retain functional expression when transfected into BALB 3T3 fibroblasts: analysis of binding, kinetics, stoichiometry, modulation by guanine nucleotide-binding proteins, and signal transduction and comparison with natively expressed receptors. Mol Pharmacol 1992, 42:1058-1068.
3. 99mTc-labeled neuroipeptides using stablished peptide analogues. Cancer Biotherapy Radiopharmaceuticals 2004, 19:181-188.
4. Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, Kwekkeboom DJ, Visser TJ, Krenning EP Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 2002, 43:1650-1656.
5. Buchegger F, Bonvin F, Kosinski M, Schaffland AO, Prior J, Reubi JC, Blaunenstein P, Tourwe D, Garcia Garayoa F, Bishof Delaloyte A Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med 2003, 44:1649-1654.
6. Bunnett N Gastrin-releasing peptide. Gut Peptides 1994, 423-445. Raven Press, New York. J.H. Walsh, G.J. Dockray (Eds.).
7. Corjay MH, Dobrzanski DJ, Way JM, Viallet J, Shapira H, Worland P, Sausville EA, Battey JF Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J Biol Chem 1991, 266:18771-18779.
8. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer cells. Nature 1985, 316(6031):823-826.
9. Dal Farra C, Sarret P, Navarro V, Botto JM, Mazella J, Vincent JP Involvement of the neurotensin receptor subtype NTR3 in the growth effect of neurotensin on cancer cell lines. Int J Cancer 2001, 92:503-509.
10. 111Inlabelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging 2003, 30:1134-1139.
11. Ehlers RA, Kim SH, Zhang Y, Ethridge RT, Murrilo C, Hellmich MR, Evans DB, Townsend CM, Evers BM Gut peptide receptor expression in human pancreatic diseases. Ann Surg 2000, 231:838-848.
12. Evers BM, Ishizuka J., Chung DC, Townsend CM, Thompson JC neurotensin expression and release in human colon cancers. Ann Surg 1992, 216:423-430.
13. Fathi Z, Corjay MH, Shapira H, Wada E, Benya R, Jensen R, Viallet J, Sausville EA, Battey JF BRS-3: novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem 1993, 268(8):5979-5984.
14. Feldman RI, Fried S, Mann E, Wu JM, Liang M Gastrin-releasing peptide receptor signaling resulting in growth inhibition. Mol Pharmacol 1996, 49:505-514.
15. Fleischmann A, Laderach U, Friess H, Buechler MW, Reubi JC Bombesin receptors in distinct tissue compartments of human pancreatic diseases. Lab Invest 2000, 80:1807-1817.
16. Gendron L, Perron A, Payet MD, Gallo-Payet N, Sarret P, Beaudet A Low-affinity neurotensin receptor (NTS2) signaling: internalization-dependent activation of ectracellular signal-regulated kinases 1/2. Mol Pharmacol 2004, 66:1421-1430.
17. Glover S, Delaney M, Dematte C, Kornberg L, Frascp M, Tan-Son-Tay R, Benya RV Phosphorylation of focal adhesion kinase tyrosine 397 critically mediates gastrin-releasing peptide's morphogenic properties. J Cell Physiol 2004, 199:77-88.
18. Guha A, Rey O, Rozengurt E Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Res 2002, 62:1632-1640.
19. Guha S, Lunn JA, Santiskulvong C, Rozengurt E Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1. Cancer Res 2003, 63:2379-2387.
20. Guo YS, Townsend CM Roles of gastrointestinal hormones in pancreatic cancer. Hepatobiliary Pancreat Surg 2000, 7:276-285.
21. Hamid QA, Corrin B, Dewar A, Hoefler H, Sheppard MN Expression of gastrin-releasing peptide (human bombesin) gene in large cell undifferentiated carcinoma of the lung. J Pathol 1990, 161:145-151.
22. Hunger-Glaser I, Salazar EP, Sinnett-Smith J, Rozengurt E Bombesin, lysophosphatidic acid and epidermal growth factor rapidly stimulated focal adhesion kinase phosphorylation at Ser-910: requirement for ERK activation. J Biol Chem 2003, 278:22631-22643.
23. Iishi H, Tatsuta M, Baba M, Yano H, Higashino K, Mukai H, Akedo H Suppression by nimesulide of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats. Clin Exp Metastasis 2003, 20:555-560.
24. Iwase K, Evers BM, Hellmich MR, Kim HJ, Higashide S, Gully D, Thompson JC, Townsend CM Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. Cancer 1997, 79:1787-1793.
25. Iwase K, Evers BM, Hellmich MR, Kim HJ, Higashide S, Gully D, Townsend CM Indirect inhibitory effect of a neurotensin receptor antagonist on human colon cancer (LoVo) growth. Surg Oncol 1996, 5:245-251.
26. Jensen JA, Carroll RE, Benya RV The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 2001, 22:689-699.
27. Jensen RT, Coy DH Progress in the development of potent bombesin receptor antagonists. Trends Pharmacol Sci 1991, 12(1):13-19.
28. Kanashiro CA, Schally AV, Cai RZ, Halmos G Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma. Anti-Cancer Drugs 2005, 16:159-165.
29. Kelley MJ, Linnoila RI, Avis IL, Georgiadis MS, Cuttitta F, Mulshine JL, Johnson BE Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 1997, 112:256-261.
30. Kim S, Kelly DR, Hellmich MR, Evers BM, Chung DH Gastrin-releasing peptide is a growth factor for human neuroblastomas. Ann Surg 2002, 235:621-629.
31. Kitabgi P Targeting neurotensin receptors with agonists and antagonists for therapeutic purposes. Curr Opin Durg Discov Devel 2002, 5:764-776.
32. Kroog GS, Jensen RT, Battey JF Mammalian bombesin receptors. Med Res Rev 1995, 15(5):389-417.
33. Lach EB, Broad S, Rozengurt E Mitogenic signaling by transfected neuromedin B receptors in Rat-1 cells. Cell Growth Differ 1995, 6(11):1427-1435.
34. Lango MN, Dyer KF, Lui VW, Gooding WE, Gubish C, Siegfried JM, Grandis JR Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J Natl Cancer Inst 2002, 94:375-383.
35. Levine L, Lucci JA3, Pazdrak B, Cheng JZ, Guo YS, Townsend CM, Hellmich HL Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003, 63:3495-3502.
36. Leyton J, Garcia-Marin J, Jensen RT, Moody TW Neurotensin tyrosin phosphorylates focal adhesion kinase in lung cancer cells. Eur J Pharmacol 2002, 442:179-186.
37. Lui VW, Thomas SM, Wentzel AM, Siegfried JM, Li JY, Grandie JR Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 2003, 22:6183-6193.
38. Maoret JJ, Anini Y, Royer-Fessard C, Gully D, Laburthe M Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cell xenografted into nude mice. Int J Cancer 1999, 80:448-454.
39. Maoret JJ, Pospai D, Royer-Fessard C, Couvineau A, Laboisse C, Voisin T, Laburthe M Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RTPCR experiments. Biochem Biophys Res Commun 1994, 203:465-471.
40. Markwalder R, Reubi J-C Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999, 59:1152-1159.
41. Martinez A A new family of angiogenic factors. Cancer Lett 2005, (in press).
42. Moody TW, Bertness V, Carney DN Bombesin-like peptides and receptors in human tumor cell lines. Peptides 1983, 4:683-686.
43. Moody TW, Chan D, Fahrenkrug J, Jensen RT Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des 2003, 9:495-509.
44. Moody TW, Chiles J, Casibang M, Moody E, Chan D, Davis TP SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides 2001, 22:109-115.
45. Moody TW, Leyton J, Garcia-Marin L, Jensen RT Nonpeptide gastrin-releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells. Eur J Pharmacol 2003, 474:21-29.
46. Moody TW, Mantey SA, Pradhan TK, Schumann M, Nakagawa T, Martinez A, Fuselier J, Coy DH, Jensen RT Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells. J Biol Chem 2004, 279:23580-23589.
47. Murphy LO, Abdel-Wahab YH, Wang QJ, Knezetic JA, Permnert J, Larsson J, Hollingsworth AM, Adrian TE Receptors and ligands for autocrine growth pathways are up-regulated when pancreatic cancer cells are adapted to serum-free culture. Pancreas 2001, 22:293-298.
48. Okusaka T, Eguchi K, Kasai T, Kurata T, Yamamoto N, Ohe Y, Tamura T, Shinkai T, Saijo N Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res 1997, 3:123-127.
49. Pansky A, Peng F, Eberhard M, Baselgia L, Siegrist W, Baumann JB, Eberle AN, Beglinger C, Hildebrand P Identification of functional GRP-preferring bombesin receptors on human melanoma cells. Eur J Clin Invest 1997, 27(1):69-76.
50. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res 1994, 54:5895-5901.
51. Plonowski A, Nagy A, Schally AV, Sun B, Groot K, Halmos G In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue AN-215. Int J Cancer 2000, 88:652-657.
52. Point-Chazel C, Portier M, Bouaboula M, Vita N, Pecceu F, Gully D, Monroe JG, Maffrand JP, Le Fur G, Casellas P Activation of mitogen-activated protein kinase couples neurotensin receptor stimulation to induction of the primary response gene Krox-24. Biochem J 1996, 320:145-151.
53. Preston SR, Miller GV, Primrose JN Bombesin-like peptides and cancer. Crit Rev Oncol Hematol 1996, 23:225-238.
54. Reubi J-C, Waser B, Friess H, Buchler M, Laissue J Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 1998, 42:546-550.
55. Reubi J-C, Waser B, Schaer JC, Laissue JA Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas. Int J Cancer 1999, 82:213-218.
56. Reubi JC, Wenger S, Schumuckli-Maurer J, Schaer JC, Gugger M Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin (6-14). Clin Cancer Res 2002, 8:1139-1146.
57. Rozengurt E Signal transduction pathways in the mitogenic response to G protein-coupled neuropeptide receptor agonists. J Cell Physiol 1998, 177:507-517.
58. Ryan RR, Weber HC, Hou W, Sainz E, Mantey SA, Battey JF, Coy DH, Jensen RT Ability of various bombesin receptor agonists and antagonists to alter intracellular signaling of the human orphan receptor BRS-3. J Biol Chem 1998, 273:13613-13624.
59. Ryder NM, Guha A, Hines OJ, Reber HA, Rozengurt E G protein-coupled receptor signaling in human ductal pancreatic cancer cells: Neurotensin responsiveness and mitogenic stimulation. J Cell Physiol 2001, 186:53-64.
60. Saurin JC, Fallavier M, Sordat B, Gevrey JC, Chayvaille JA, Abello J Bombesin stimulates invasion and migration of Isrecol colon carcinoma cells in a Rho-dependent manner. Cancer Research 2002, 62:4829-4835.
61. Schally AV, Comary-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G Hypothalamic hormones and cancer. Front Neuroendocrinol 2001, 22:248-291.
62. Schally AV, Nagy A Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999, 141:1-14.
63. Sehgal I, Powers S, Huntley B, Powis G, Pittelkow M, Maihle NJ Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci U S A 1994, 91:4673-4677.
64. Sharif TR, Luo W, Sharif M Functional expression of bombesin receptor in most adult and pediatric human glioblastoma cell lines; role in mitogenesis and in stimulating the mitogen-activated protein kinase pathway. Mol Cell Endocrinol 1997, 130:119-130.
65. Shibayama T, Ueoka H, Nishii K, Kiura K, Tabata M, Miyatake K, Kitajima T, Harada M Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer 2001, 32:61-69.
66. Shulkes A Neurotensin. Gut Peptides: Biochemistry and Physiology 1994, 371-388. Raven Press, New York. J.H. Walsh, G.J. Dockray (Eds.).
67. Siegfried JM, Krishnamachary N, Davis AG, Gubish C, Hunt JD, Shriver SP Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. Pulm Pharmacol Ther 1999, 12:291-302.
68. Smith CJ, Volkert WA, Hoffman TJ Gastrin releasing peptide (GRP), receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol 2003, 30:861-868.
69. Somai S, Gompel A, Rostene W, Forgez P Neurotensin counteracts apoptosis in breast cancer cells. Biochem Biophy Res Commun 2002, 295:482-488.
70. Sumi S, Evers BM, Townsend CM, Yoshinaga K, Uchida T, Murakami M, Sato K, Ishizuka J, Thompson JC Comparative effects of neurotensin and neuromedin N on growth of human pancreatic cancer, MIS PaCa-2. Surg Oncol 1993, 2:267-272.
71. Tatsuta M, Iishi H, Baba H, Taniguchi H Enhancement by neurotensin of experimental carcinogenesis induced in rat colon by azoxymethane. Br J Cancer 1990, 62:368-371.
72. Tatsuta M, Iishi H, Baba H, Taniguchi H Promotion by neurotensin of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitroguanidine in Wistar rats. Cancer Res 1989, 49:843-846.
73. Thomas RP, Hellmich MR, Townsend CM, Evers BM Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocr Rev 2003, 24:571-599.
74. Vincent JP, Mazella J, Kitabgi P Neurotensin and neurotensin receptors. Trends Pharmacol Sci 1999, 20:302-309.
75. Wang L, Friess H, Zhu Z, Graber H, Zimmermann A, Korc M, Reubi J-C, Buchler MW Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. Clin Cancer Res 2000, 6:566-571.
76. Wang QJ, Knezetic JA, Schally AV, Pour PM, Adrian TE Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway. Int J Cancer 1996, 68:528-534.
77. Yano T, Pinski J, Szepeshazi K, Halmos G, Radulovic S, Groot K, Schally AV Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer zenografts in athymic nude mice. Cancer 1994, 73:1229-1238.
78. Yegen BC Bombesin-like peptides: candidates as diagnostic and therapeutic tools. Curr Pharm Des 2003, 9:1013-1022.
79. Yoshinaga K, Evers BM, Izukura M, Parekh D, Uchida T, Townsend CM, Thompson JC Neurotensin stimulates growth of colon cancer. Surg Oncol 1992, 1:127-134.
80. Zhang Q, Thomas SM, Smithgall TE, Siegfried JM, Kamens J, Gooding WE, Grandis JR SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004, 64:6166-6173.
81. Zhou J, Chen J, Mokotoff M, Ball ED Targeting gastrin-releasing peptide receptors for cancer treatment. Anti-Cancer Drugs 2004, 15:921-927.